Ownership and insider activity for Biodesix, Inc. (BDSX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
Price
| Price | $28.56 |
| Market Cap | $232M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-12 | SCHULER JACK W | P-Purchase | 15,000 | $367K |
| 2026-08-11 | SCHULER JACK W | P-Purchase | 13,700 | $329K |
| 2026-08-10 | SCHULER JACK W | P-Purchase | 13,900 | $337K |
| 2026-06-30 | PATIENCE JOHN | M-Exempt | 1,361 | |
| 2026-06-30 | PATIENCE JOHN | M-Exempt | 1,361 | |
| 2026-03-31 | PATIENCE JOHN | M-Exempt | 1,361 | |
| 2026-03-31 | PATIENCE JOHN | M-Exempt | 1,361 | |
| 2026-02-20 | Pestano Gary Anthony | M-Exempt | 1,528 | |
| 2026-02-23 | Pestano Gary Anthony | S-Sale | 556 | $7K |
| 2026-02-20 | Pestano Gary Anthony | M-Exempt | 1,528 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.9M | $5.3M | $62.1M | $32.7M | $43.1M | $26.3M | $26.2M | $19.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.9M | $5.3M | $15.3M | $3.7M | $5.1M | $7.7M | $8.6M | $9.0M |
| Inventory | $700000 | $800000 | $3.2M | $2.9M | $1.4M | $1.4M | 0 | 0 |
| Total Current Assets | $9.9M | $12.7M | $86.1M | $43.6M | $53.3M | $39.7M | $39.5M | $32.5M |
| Property, Plant & Equipment | $1.4M | $2.1M | $3.2M | $4.2M | $8.8M | $29.6M | $29.6M | $27.8M |
| Goodwill | $10.8M | $11.6M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M |
| Intangible Assets | $16.9M | $15.1M | $13.3M | $11.6M | $9.8M | $7.9M | $5.9M | $3.9M |
| Total Assets | $39.1M | $41.6M | $121.1M | $76.1M | $92.9M | $99.1M | $97.2M | $87.5M |
| Accounts Payable | $886000 | $1.7M | $9.0M | $1.7M | $1.7M | $2.9M | $2.2M | $3.1M |
| Short-term Debt | 0 | $12.2M | $11.8M | $19000 | $49000 | $51000 | $21000 | $6000 |
| Total Current Liabilities | $4.5M | $22.6M | $32.1M | $29.0M | $22.8M | $33.4M | $14.3M | $17.4M |
| Long-term Debt | $23.1M | $23.8M | $15.9M | $10.0M | $25.0M | $35.2M | $36.4M | $47.4M |
| Total Liabilities | $237.1M | $270.2M | $79.9M | $56.4M | $72.3M | $94.5M | $76.4M | $89.9M |
| Retained Earnings | -$200.1M | -$230.9M | -$258.8M | -$302.0M | -$367.4M | -$419.6M | -$462.5M | -$497.8M |
| Total Equity | -$198.0M | -$228.5M | $41.2M | $19.7M | $20.6M | $4.6M | $20.9M | -$2.5M |
| Total Debt | $23.1M | $36.0M | $27.8M | $10.0M | $31.9M | $60.7M | $62.0M | $72.9M |
| Net Debt | $17.2M | $30.7M | -$34.4M | -$22.7M | -$11.2M | $34.4M | $35.7M | $53.9M |
| Working Capital | $5.4M | -$9.9M | $54.0M | $14.7M | $30.5M | $6.3M | $25.2M | $15.1M |
Financial Health
| Debt / Equity | 7.85 |
| Current Ratio | 2.85 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -7.45 |
Profitability
| Return on Equity | -788.19% |
| Return on Invested Capital | -25.22% |
| Return on Assets | -29.12% |
| Gross Margin | 82.50% |
| Operating Margin | -20.01% |
| Net Margin | -26.97% |
Related companies: ALGS · INMB · MRSN · NOTV · OKUR · PDSB · SKYE
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BDSX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks